Maxim Group set a $84.00 price target on Gilead Sciences (NASDAQ:GILD) in a research note published on Tuesday, February 5th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on GILD. Raymond James reiterated a buy rating on shares of Gilead Sciences in a research note on Thursday, November 1st. BidaskClub downgraded Gilead Sciences from a buy rating to a hold rating in a research report on Wednesday, October 24th. Piper Jaffray Companies cut Gilead Sciences from an overweight rating to a neutral rating and dropped their target price for the stock from $85.00 to $75.00 in a report on Friday, October 26th. Morgan Stanley raised their price target on Gilead Sciences from $85.00 to $86.00 and gave the company an equal weight rating in a report on Wednesday, December 19th. Finally, Evercore ISI reiterated a buy rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of Hold and a consensus target price of $82.56.
Shares of NASDAQ GILD traded up $0.99 during trading on Tuesday, reaching $66.01. The stock had a trading volume of 5,864,220 shares, compared to its average volume of 7,207,729. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09. Gilead Sciences has a one year low of $60.32 and a one year high of $82.71. The company has a market capitalization of $85.04 billion, a price-to-earnings ratio of 10.73, a price-to-earnings-growth ratio of 4.14 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.78 EPS. As a group, equities analysts predict that Gilead Sciences will post 6.23 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 37.07%.
In other news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the transaction, the director now owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the transaction, the director now directly owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The disclosure for this sale can be found here. Corporate insiders own 1.16% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 199,789.8% in the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Gilead Sciences by 5,733.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 28,491,386 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Gilead Sciences by 22.5% during the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after buying an additional 12,818,301 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Gilead Sciences by 285.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock valued at $308,688,000 after buying an additional 2,959,697 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Gilead Sciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after buying an additional 2,195,948 shares during the last quarter. 77.76% of the stock is currently owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Trading signals using Bollinger bands
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.